ÄÁÅÙÃ÷»ó¼¼º¸±â

COVID-19 ¹ÙÀÌ·¯½ºÀÇ ÀÀ°í ±â´ÉÀå¾Ö ¹× Ä¡·á¿¡ ´ëÇÑ Àü¹®°¡ Áø´Ü
COVID-19 ¹ÙÀÌ·¯½ºÀÇ ÀÀ°í ±â´ÉÀå¾Ö ¹× Ä¡·á¿¡ ´ëÇÑ Àü¹®°¡ Áø´Ü
  • ÀúÀÚJing-Chun Song, Gang Wang, Wei Zhang,Yang Zhang, Wei-Qin Li, Zhou Zhou,¿Ü Àú
  • ÃâÆÇ»ç¾ÆÁø
  • ÃâÆÇÀÏ2020-07-12
  • µî·ÏÀÏ2020-12-21
º¸À¯ 1, ´ëÃâ 0, ¿¹¾à 0, ´©Àû´ëÃâ 5, ´©Àû¿¹¾à 0

Ã¥¼Ò°³

Since December 2019, a novel type of coronavirus disease (COVID-19) in Wuhan
led to an outbreak throughout China and the rest of the world. To date, there
have been more than 1,260,000 COVID-19 patients, with a mortality rate of
approximately 5.44%. Studies have shown that coagulation dysfunction is a major
cause of death in patients with severe COVID-19. Therefore, the People¡¯s
Liberation Army Professional Committee of Critical Care Medicine and Chinese
Society on Thrombosis and Hemostasis grouped experts from the frontline of the
Wuhan epidemic to come together and develop an expert consensus on diagnosis
and treatment of coagulation dysfunction associated with a severe COVID-19
infection. This consensus includes an overview of COVID-19-related coagulation
dysfunction, tests for coagulation, anticoagulation therapy, replacement therapy,
supportive therapy and prevention.
The consensus produced 18 recommendations which are being used to guide clinical
work.
Keywords: COVID-19, Severe, Coagulation dysfunction, Diagnosis, Treatment

¸ñÂ÷

Á¦ 1Æí Äڷγª¹ÙÀÌ·¯½º Á¤ÀÇ
1. Äڷγª¹ÙÀÌ·¯½º°¨¿°Áõ-19(Covid-19) Á¤º¸ 7
2. Äڷγª¹ÙÀÌ·¯½º ºÐ·ù ¹× Æ¯¼º 9
3. Äڷγª¹ÙÀÌ·¯½º ÀüÀÚÇö¹Ì°æ ÇüÅ 11
4. Äڷγª¹ÙÀÌ·¯½º ±¸Á¶ (Covid-19 Organization) 13
5. Äڷγª19: È¯°æ¿¡ Áö¼ÓÀûÀΠ¿µÇâÀ» ¹ÌÄ¥±î? 19
6. Ä¡·á¹ý(Therapeutical Method) 22

Á¦ 2Æí ¿¬±¸³í¹®
Chinese expert consensus on diagnosis and treatment of coagulation
dysfunction in COVID-19

1. Overview 24
2. Anticoagulation therapy 25
3. Replacement treatment 28
4. Prevention 29
5. References 31

ÇÑÁÙ ¼­Æò